Research led by the St. Jude Children’s Research Hospital – Washington University Pediatric Cancer Genome Project has identified a fusion gene responsible for almost 30 percent of a rare subtype of childhood leukemia with an extremely poor prognosis.
The finding offers the first evidence of a mistake that gives rise to a significant percentage of acute megakaryoblastic leukemia (AMKL) cases in children. AMKL accounts for about 10 percent of pediatric acute myeloid leukemia (AML). The discovery paves the way for desperately needed treatment advances.
To view Multimedia News Release, go to http://www.multivu.com/mnr/58586-st-jude-children-s-research-hospital-gene-sequencing-childhood-leukemia
From January 25-27 more than 4,000 college and high school basketball coaches across the United States will be making much more than just a fashion statement when they sport tennis shoes with their suits during the 10th annual Suits and Sneakers weekend.
Suits and Sneakers weekend is an annual event coordinated by the Coaches vs. Cancer program, a nationwide collaboration between the American Cancer Society and the National Association of Basketball Coaches. The Coaches vs. Cancer program empowers basketball and other athletic coaches to save lives from cancer by leveraging their community leadership to raise awareness and funds for the American Cancer Society.
To view Multimedia News Release, go to http://www.multivu.com/mnr/59447-american-cancer-society-10th-annual-suits-and-sneakers-weekend
The public is generally satisfied with cancer research progress over the past 20 years. However, they believe it takes too long for new cancer medicines to reach patients and that their countries invest too little in fighting cancer. Most fear that the current economic crisis will slow cancer research progress. This is according to the PACE Cancer Perception Index: A Six-Nation, Public Opinion Survey of Cancer Knowledge and Attitudes, released today in advance of World Cancer Day, which is recognized on February 4, 2013.
To view Multimedia News Release, go to http://www.multivu.com/mnr/60140-lilly-oncology-pace-cancer-perception-index
The USPSTF today issued a draft recommendation giving its second highest approval rating for CT screening for lung cancer for those at high risk, a move that if approved in final form, will trigger Medicare and insurance coverage and bring about a dramatic drop in the leading cause of cancer deaths.
Today, LCA also launched its Risk Navigator tool – www.AtRiskForLungCancer.org. Additionally, it expanded the hours of its support line – (800) 298-2436 – operating 8 a.m. to 7 p.m. EST. LCA will also launch a national educational advertising campaign in September to encourage the public to know their risk for lung cancer.
To view the Multimedia News Release, go to http://www.multivu.com/mnr/62719-lung-cancer-alliance-uspstf-recommends-ct-screening-for-lung-cancer
“You have cancer.” Those three words are among the most dreaded and powerful a person can hear. In the case of Tony Harnell, the diagnosis of thyroid cancer was doubly frightening.
A vocalist/songwriter with a four-octave range, Harnell had toured in the U.S. with likes of Stryper, Twisted Sister and Great White and appeared on stages worldwide, entertaining legions of fans as lead singer with hard-rock band TNT.
To view Multimedia News Release, go to http://www.multivu.com/mnr/62578-american-college-endocrinology-tony-harnell-advocate-thyroid-cancer-aware
Nucletron, an Elekta company, and the world leader in brachytherapy, has launched Esteya®, a new approach for treating patients with skin cancer.
Over the last 30 years, more people were diagnosed with skin cancer worldwide than all other cancers combined, making it the most common type of cancer1. This represents a challenge for health care providers in the years to come. With a cure rate of more than 95 percent2, electronic brachytherapy offers a refined treatment modality with excellent cosmesis.
To view Multimedia News Release, go to http://www.multivu.com/mnr/62823-elekta-nucletron-esteya-electronic-brachytherapy-treating-skin-cancer
In the U.S., approximately 159,000 women are living with metastatic breast cancer. To raise awareness of Metastatic Breast Cancer Awareness Day on October 13, MedImmune Specialty Care Division of AstraZeneca (NYSE: AZN) is launching the My+Story online resource center, which highlights the needs of women living with metastatic breast cancer and calls attention to metastatic disease as a key component of October’s National Breast Cancer Awareness Month. Metastatic Breast Cancer Awareness Day was officially recognized by the U.S. Congress in 2009, following a grassroots awareness effort led by members of the Metastatic Breast Cancer Network (MBCN).
To view Multimedia News Release, go to http://www.multivu.com/mnr/63080-astrazeneca-metastatic-breast-cancer-awareness
Nearly 90 percent of children and adults with a highly aggressive form of acute lymphoblastic leukemia (ALL) showed no evidence of cancer after receiving a novel, personalized cell therapy that reprograms a patient’s immune system. In pilot studies of bioengineered T cells that attack leukemia, 24 of 27 patients (89%) experienced complete responses within 28 days after treatment. In all, 27 patients received the treatment--22 children treated at The Children’s Hospital of Philadelphia and five adults treated at the Hospital of the University of Pennsylvania.
To view the Multimedia News Release, go to http://www.multivu.com/mnr/64394-chop-penn-harness-engineered-t-cells-eliminate-tumors-in-blood-leukemia
Lung cancer is the most common cause of cancer-related death worldwide, with the highly malignant small cell lung cancer having the worst prognosis. In recent years the surge of immunotherapy has given cancer sufferers new hope.
To view the Multimedia News Release, go to http://www.multivu.com/mnr/64826-issels-recurrent-lung-cancer-responds-to-integrative-immunotherapy
Lung cancer is the most common cause of cancer-related death worldwide, with the highly malignant small cell lung cancer having the worst prognosis. In recent years the surge of immunotherapy has given cancer sufferers new hope.
To view the Multimedia News Release, go to http://www.multivu.com/mnr/65511-issels-integrative-immunotherapy-non-toxic-treatment-lung-cancer
